EUVIMEDEUVIMED entdecken
KorrekturOpen Access

Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System

Nazia Rashid, Paul Saenger, Yi-Lin Wu, Heike Woehling, Matthew Frankel, Fima Lifshitz, Michael Muenzberg, Robert Rapaport

Biologics in Therapy · 2014

DOI: 10.1007/s13554-014-0020-6 ↗

Kurz gefasst

Korrektur in der Zeitschrift Biologics in Therapy, 2014. Verfasst von Nazia Rashid und 7 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente, Southern California Region, Drug Information Services, Downey, CA, USA. Nazia.X.Rashid@kp.org. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The authors of the above-mentioned paper noticed some errors subsequent to publication and would like to make the following corrections. On pages 5 and 6, Table 1 will include a footnote for the prior non-Omnitrope rhGH therapy: ‘‘These patients are not mutually exclusive, they could have been on multiple GH therapies prior to switching to Omnitrope’’. On page 10 under the heading Discussion the recommended dose of GH therapy in TS patients preand post-switch should be 0.33 mg/kg/week. The sentence should now read ‘‘We recognize that the GH therapy dose that was used in TS patients preand postswitch was less than the recommended dose of 0.33 mg/kg/week’’.

Autor:innen und Institutionen

  • Kaiser Permanente, Southern California Region, Drug Information Services, Downey, CA, USA. Nazia.X.Rashid@kp.org.
  • Department of Pediatrics, Albert Einstein College of Medicine, New York, NY, USA.
  • Department of Research and Evaluation, Kaiser Permanente, Pasadena, CA, USA.
  • Sandoz International GmbH, Holzkirchen, Germany.
  • Sandoz Inc., Princeton, NJ, USA.
  • Pediatric Sunshine Academics, Santa Barbara, CA, USA.

Zitieren

APA

Rashid, N., Saenger, P., Wu, Y. L., Woehling, H., Frankel, M., Lifshitz, F., Muenzberg, M., & Rapaport, R. (2014). Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System. Biologics in Therapy. https://doi.org/10.1007/s13554-014-0020-6

Vancouver

Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz F, et al. Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System. Biologics in Therapy. 2014. doi:10.1007/s13554-014-0020-6

BibTeX
@article{Rashid2014,
  author = {Rashid, Nazia and Saenger, Paul and Wu, Yi-Lin and Woehling, Heike and Frankel, Matthew and Lifshitz, Fima and Muenzberg, Michael and Rapaport, Robert},
  title = {Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System},
  journal = {Biologics in Therapy},
  year = {2014},
  doi = {10.1007/s13554-014-0020-6}
}
Kostenlos starten →